Profile
Bryan Fedorak is the founder of Bartesian, Inc. He is currently working as a Director at Metabolomic Technologies, Inc.
Bryan Fedorak active positions
| Companies | Position | Start |
|---|---|---|
Bartesian, Inc.
 Bartesian, Inc. Industrial MachineryProducer Manufacturing Bartesian, Inc. engages in the creation of cocktail drinks business. It offers capsule drink-maker such as vodka, rum, tequila, margarita, and gin. The company was founded by Bryan Fedorak and Ryan Close and is headquartered in Kitchener, Canada. | Founder | - |
Metabolomic Technologies, Inc.
 Metabolomic Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Bartesian, Inc.
Bartesian, Inc. Industrial MachineryProducer Manufacturing Bartesian, Inc. engages in the creation of cocktail drinks business. It offers capsule drink-maker such as vodka, rum, tequila, margarita, and gin. The company was founded by Bryan Fedorak and Ryan Close and is headquartered in Kitchener, Canada. | Producer Manufacturing |
Metabolomic Technologies, Inc.
Metabolomic Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Metabolomic Technologies, Inc. is a Canadian company that specializes in developing in vitro diagnostics using metabolomics. Metabolomic Technologies was founded by Haili Wang and Richard Fedorak and is based in Edmonton, CA. The company's lead product, PolypDX™, is a urine-based screening test for colorectal cancer. The company utilizes a unique metabolomics platform to identify distinct metabolic fingerprints and develop accurate diagnostic tests. | Commercial Services |
- Stock Market
- Insiders
- Bryan Fedorak
